Trials / Completed
CompletedNCT03059797
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Small Cell Lung Cancer(ALTER1202)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare the effects and safety of Anlotinib with placebo in patients with small cell lung cancer(SCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle |
| DRUG | Placebo | Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle |
Timeline
- Start date
- 2017-03-27
- Primary completion
- 2018-06-30
- Completion
- 2019-05-06
- First posted
- 2017-02-23
- Last updated
- 2019-05-16
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03059797. Inclusion in this directory is not an endorsement.